Adicet Bio Inc (ACET)

Currency in USD
0.486
-0.006(-1.22%)
Closed·
0.448-0.038(-7.82%)
·
Unusual Post-Market activity
ACET is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.4720.498
52 wk Range
0.4471.110
Key Statistics
Prev. Close
0.486
Open
0.49
Day's Range
0.472-0.498
52 wk Range
0.447-1.11
Volume
1.69M
Average Volume (3m)
2.49M
1-Year Change
-45.62%
Book Value / Share
1.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACET Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.167
Upside
+1,374.62%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Adicet Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Adicet Bio Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin’s lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio Inc SWOT Analysis


Gamma-Delta Pionee
Adicet Bio leads in engineered gamma-delta T cell therapies, with promising candidates for lupus nephritis and renal cell carcinoma in Phase 1 trials
Financial Fortitude
Strong cash position of $150.4M supports ongoing clinical trials, though rapid cash burn rate poses future funding challenges
Expanding Horizons
Explore Adicet's ambitious pipeline expansion into multiple autoimmune conditions, showcasing the versatility of its innovative platform
Market Valuation
With analyst price targets ranging from $4 to $8 per share, Adicet's current trading price of $0.69 presents a potential asymmetric upside opportunity
Read full SWOT analysis

Compare ACET to Peers and Sector

Metrics to compare
ACET
Peers
Sector
Relationship
P/E Ratio
−0.7x−1.3x−0.6x
PEG Ratio
−0.040.020.00
Price/Book
0.7x1.5x2.6x
Price / LTM Sales
-5.0x3.2x
Upside (Analyst Target)
-468.3%41.8%
Fair Value Upside
Unlock28.5%5.1%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.167
(+1,374.62% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Hold---Maintain19/11/2025
H.C. Wainwright
Buy9.00+1,751.85%4.00Maintain07/11/2025
Citizens
Hold---Maintain08/10/2025
Guggenheim
Buy8.00+1,546.09%7.00Maintain07/10/2025
Citizens JMP
Hold---Maintain09/09/2025

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.29 / -0.30
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

5.8400
XCUR
-0.68%
2.180
CABA
-8.79%
0.5200
COSM
-1.89%
1.360
FLUX
-1.45%
3.670
QNCX
+0.55%

FAQ

What Is the Adicet Bio (ACET) Share Price Today?

The live Adicet Bio share price today is 0.486

What Stock Exchange Does Adicet Bio (ACET) Trade On?

Adicet Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Adicet Bio?

The stock symbol (also called a 'ticker') for Adicet Bio is "ACET."

What Is the Current Adicet Bio Market Cap?

As of today, Adicet Bio market capitalisation is 78.57M.

What Is Adicet Bio's (ACET) Earnings Per Share (TTM)?

The Adicet Bio EPS is currently -1.26 (Trailing Twelve Months).

When Is the Next Adicet Bio Earnings Date?

Adicet Bio's next earnings report will be released on 05 Mar 2026.

Is ACET a Buy or Sell From a Technical Analyst Perspective?

Based on today's Adicet Bio moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Adicet Bio Stock Split?

Adicet Bio has split 1 times. (See the ACET stock split history page for full effective split date and price information.)

How Many Employees Does Adicet Bio Have?

Adicet Bio has 152 employees.

What is the current trading status of Adicet Bio (ACET)?

As of 24 Dec 2025, Adicet Bio (ACET) is trading at a price of 0.486, with a previous close of 0.486. The stock has fluctuated within a day range of 0.472 to 0.498, while its 52-week range spans from 0.447 to 1.110.

What Is Adicet Bio (ACET) Price Target According to Analysts?

The average 12-month price target for Adicet Bio is USD7.16667, with a high estimate of USD9 and a low estimate of USD5. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1,374.62% Upside potential.

What Is the ACET After Hours Price?

ACET's last after hours stock price is 0.448, the stock has decreased by -0.038, or -7.820%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.